Combined Use of Endonasal Retinalamin Electrophoresis and Lidase Magnetophoresis Enhances the Regenerative and Recovery Effects of Anti-VEGF Therapy in the Treatment of Non-Ischemic Branch Retinal Vein Occlusion: A Retrospective Cohort Study

Despite the documented efficacy and widespread clinical application of lidase magnetophoresis (LMP) and endonasal retinalamin electrophoresis (ERE) in Russia for the management of retinal vein occlusion (RVO), the synergistic potential of these methods remains insufficiently studied in current literature. Purpose: To evaluate the efficacy of LMP and ERE combined with intravitreal ranibizumab for the management of non-ischemic superior temporal RVO by analyzing longitudinal changes in central retinal thickness and total macular volume immediately post-treatment and at a three-month follow-up. Materials and Methods: In this retrospective, single-center, three-arm cohort study, we analyzed the clinical records of patients with non-ischemic superior temporal RVO who underwent LMP and ERE in combination with anti-VEGF therapy. In the final analysis were included 71 patients who underwent anti-VEGF monotherapy (control group). Additional to anti-VEGF therapy 71 patients passed LMP (LMP group) and 72 patients completed LMP and ERE (LMP + ERE group). Central retinal thickness and total macular volume were measured using optical coherence tomography at baseline, at one- and three-months post-treatment, and at the end of the follow-up period. Best-corrected visual acuity was evaluated at the same intervals. Results: A comparative analysis with anti-VEGF monotherapy revealed that combined application of ERE and LMP offers superior efficacy in reducing central retinal thickness by an additional 12.2% (t = 4.21, p-value = 0.0001, Cohen's d = 0.72) and total macular volume by 13.3% (t = 4.31, p-value = 0.0001, Cohen's d = 0.76) and in im-proving visual function by 66.7 (t = 30.2, p-value = 0.0001, Cohen's d = 6.5). Conclusions: Innovative complex use of ERE and LMP in the second month after the start of treatment with intravitreal anti-VEGF therapy enhances the protective and regenerative effect of anti-VEGF therapy. Application of this method leads to a more rapid reduction in central retinal thickness and total macular volume, which is critical for preventing permanent vision loss, scotoma, and optic nerve atrophy in patients following RVO.

1. Jonas J.B., Monés J., Glacet-Bernard A., Coscas G. Retinal vein occlusions. Dev Ophthalmol 2017; 58: 139-167. https://doi.org/10.1159/000455278.

2. Khayat M., Williams M., Lois N. Ischemic retinal vein occlusion: characterizing the more severe spectrum of retinal vein occlusion. Surv Ophthalmol 2018; 63(6): 816-850. https://doi.org/10.1016/j.survophthal.2018.04.005.

3. Song P., Xu Y., Zha M., et al. Global epidemiology of retinal vein occlusion: a systematic re-view and meta-analysis of prevalence, incidence, and risk factors. J Glob Health 2019; 9(1): 010427. https://doi.org/10.7189/jogh.09.010427.

4. Li W., Bian L., Ma B., et al. Interpretable detection of diabetic retinopathy, retinal vein occlusion, age-related macular de-genera-tion, and other fundus conditions. Diagnostics (Basel) 2024; 14 (2): 121. https://doi.org/10.3390/diagnostics14020121.

5. Ponto K.A., Elbaz H., Peto T., et al. Prevalence and risk factors of retinal vein occlusion: the Gutenberg Health Study. J Thromb Haemost 2015; 13 (7): 1254-1263. https://doi.org/10.1111/jth.12982.

6. Smekalkina L.V., Safonicheva O.G., Kabardina E.V., et al. Current understanding of retinal vein thrombosis in older adults: A review of the literature. Clin Interv Aging 2025; 3 (20): 2399-2407. https://doi.org/10.2147/CIA.S548403.

7. Hariprasad S.M., Holz F.G., Asche C.V., et al. Clinical and socioeconomic burden of retinal diseases: Can biosimilars add value? A narrative review. Ophthalmol Ther 2025; 14 (4): 621-641. https://doi.org/10.1007/s40123-025-01104-3.

8. Park S.J., Choi N.K., Park K.H., Woo S.J. Nationwide incidence of clinically diagnosed retinal vein occlu-sion in Korea, 2008 through 2011: preponderance of women and the impact of aging. Ophthalmology 2014; 121 (6): 1274-1280. https://doi.org/10.1016/j.ophtha.2013.12.024.

9. Shin K.U., Lee J.Y., Han K., Song S.J. Sex-specific age threshold for increased risk of retinal vein occlusion in Koreans. Thromb Res 2018; 167: 60-63. https://doi.org/10.1016/j.thromres.2018.05.020.

10. Song P., Xu Y., Zha M., et al. Global epidemiology of retinal vein occlusion: a systematic re-view and meta-analysis of prevalence, incidence, and risk factors. J Glob Health 2019; 9 (1): 010427. https://doi.org/10.7189/jogh.09.010427.

11. Zhang X.T., Zhong Y.F., Xue Y.Q., et al. Clinical features of central retinal vein occlusion in young patients. Ophthalmol Ther 2022; 11 (4): 1409-1422. https://doi.org/10.1007/s40123-022-00534-7.

12. Darabuş D.M., Dărăbuş R.G., Munteanu M. The diagnosis and treatment of branch retinal vein occlusions: An update. Biomedicines 2025; 5 (13): 105. https://doi.org/10.3390/biomedicines13010105.

13. Lang G.E., Lang S.J. Venöse Gefäßverschlüsse der Retina [Retinal Vein Occlusions]. Klin Monbl Augenheilkd 2018; 235 (11): 1297-1315. (In German) https://doi.org/10.1055/a-0662-1197.

14. Devi V.L.J., Panigrahi P.K., Minj A., Hanisha D. Clinical profile of patients with retinal vein occlusion and its correlation with serum homocysteine levels. BMC Ophthalmol 2025; 25 (1): 458. https://doi.org/10.1186/s12886-025-04285-4.

15. Schmidt-Erfurth U., Garcia-Arumi J., Gerendas B.S., et al. Guidelines for the management of retinal vein occlusion by the European Society of Retina Specialists (EURETINA). Ophthalmologica 2019; 242 (3): 123-162. https://doi.org/10.1159/000502041.

16. Sivaprasad S., Amoaku W.M., Hykin P. RVO Guideline Group. The Royal College of Ophthalmologists Guidelines on retinal vein occlusions: executive summary. Eye (Lond) 2015; 29 (1): 1633-1638. https://doi.org/10.1038/eye.2015.164.

17. Basilious A., Duncan J., Smuck B., et al. Treatment discontinuation patterns of anti-VEGF in retinal vein occlusion. Can J Ophthalmol 2024; 59 (5): 341-349. https://doi.org/10.1016/j.jcjo.2023.08.005.

18. Spooner K.L., Fraser-Bell S., Hong T., et al. Long-term outcomes of anti-VEGF treatment of retinal vein occlusion. Eye (Lond) 2022; 36 (6): 1194-1201. https://doi.org/10.1038/s41433-021-01620-z.

19. Namvar E., Yasemi M., Nowroozzadeh M.H., Ahmadieh H. Intravitreal injection of anti-vascular endothelial growth factors combined with corticosteroids for the treatment of macular edema secondary to retinal vein occlusion: A systematic review and meta-analysis. Semin Ophthalmol 2024; 39 (1): 109-119. https://doi.org/10.1080/08820538.2023.2249527.

20. Nicholson L., Talks S.J., Amoaku W., et al. Retinal vein occlusion (RVO) guideline: ex-ecutive summary. Eye (Lond) 2022; 36 (5): 909-912. https://doi.org/10.1038/s41433-022-02007-4.

21. Zhang X.T., Zhong Y.F., Xue Y.Q., et al. Clinical features of central retinal vein occlusion in young patients. Ophthalmol Ther 2022; 11 (4): 1409-1422. https://doi.org/10.1007/s40123-022-00534-7.

22. Rehak M., Wiedemann P. Retinal vein thrombosis: pathogenesis and management. J. Thromb. Haemost 2010; 8: 1886–1894. https://doi.org/10.1111/j.1538-7836.2010.03909.x

23. Noma H., Yasuda K., Shimura M. Cytokines and pathogenesis of central retinal vein occlusion. J Clin Med 2020; 9 (11): 3457. https://doi.org/10.3390/jcm9113457

24. Darabuş D.M., Dărăbuş R.G., Munteanu M. The diagnosis and treatment of branch retinal vein occlusions: An update. Biomedicines 2025; 13 (1): 105. https://doi.org/10.3390/biomedicines13010105.

25. Noh S.Y., Lee J.H., Jeong, W.J. Branch retinal vein occlusion with arteriovenous crossing. J. Retin 2023; 8: 36–41. https://doi.org/10.21561/jor.2023.8.1.36.

26. Lendzioszek M., Bryl A., Poppe E., et al. Retinal vein occlusion-background knowledge and foreground knowledge pro-spects-A review. J Clin Med 2024; 13 (13): 3950. https://doi.org/10.3390/jcm13133950.

27. Cochran M.L., Mahabadi N., Czyz C.N. Branch retinal vein occlusion. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2025, Available from: https://www.ncbi.nlm.nih.gov/books/NBK535370/

28. Ashraf M., Souka A.A., Singh, R.P. Central retinal vein occlusion: modifying current treatment protocols. Eye (Lond). 2016; 30 (4): 505-514. https://doi.org/10.1038/eye.2016.10.

29. Casselholmde Salles M., Kvanta A., Amrén U., Epstein D. Optical coherence tomography angiography in central retinal vein occlusion: correlation between the foveal avascular zone and visual acuity. Invest Ophthalmol Vis Sci 2016; 57 (9): OCT242-6. https://doi.org/10.1167/iovs.15-18819.

30. Soecknick F., Breher K., Nafar Z., et al. The clinical evaluation of a widefield lens to expand the field of view in optical coherence tomography (OCT-A). Sci Rep 2024; 14: 6936. https://doi.org/10.1038/s41598-024-57405-3.

31. Burchard C.V., Roider J., Kepp T. Analysis of OCT scanning parameters in AMD and RVO. Diagnostics (Basel) 2024; 14 (5): 516. https://doi.org/10.3390/diagnostics14050516.

32. Gupta S., Thapa R., Pradhan E., et al. Patterns of macular edema in branch retinal vein occlusion diagnosed by optical coherence tomography. Nepal J Ophthalmol 2023; 15 (30): 55-62. doi: 10.3126/nepjoph.v15i2.29763.

33. Haydinger C.D., Ferreira L.B., Williams K.A., Smith J.R. Mechanisms of macular edema. Front Med (Lausanne) 2023; 7 (10): 1128811. https://doi.org/10.3389/fmed.2023.1128811.

34. Martinet V., Guigui B., Glacet-Bernard A., et al. Macular edema in central retinal vein occlusion: correlation between optical coherence tomography, angiography and visual acuity. Int Ophthalmol 2012; 32 (4): 369-377. https://doi.org/10.1007/s10792-012-9578-5.

35. Rotsos T.G., Moschos M.M. Cystoid macular edema. Clin Ophthalmol 2008; 2 (4): 919-930. https://doi.org/10.2147/opth.s4033.

36. Ravalico G., Battaglia Parodi M. Exudative retinal detachment subsequent to retinal vein occlusion. Ophthalmologica 1992; 205 (2): 77-82. https://doi.org/10.1159/000310316.

37. Qi Y., Scotland D.H., Zhang C., Xu, J. Changes of choroidal thickness and choroidal vascularity index in patients with macular edema secondary to branch retinal vein occlusion after intravitreal ranibizumab. Int J Retina Vitreous 2025; 11 (1): 99. https://doi.org/10.1186/s40942-025-00727-9.

38. Şekeroğlu M.A., Taşkale F.B., Doğuizi S., Yılmazbaş P. Prevalence of serous macular detachment in recurrent macular edema secondary to retinal vein occlusion. Turk J Ophthalmol 2022; 52 (4): 276-280. https://doi.org/10.4274/tjo.galenos.2021.02582.

39. Jing Y., Li D. Faricimab for retinal vein occlusion: a review of current evidence and future perspectives. Front Pharmacol 2025; 14 (16): 1646806. https://doi.org/10.3389/fphar.2025.1646806.

40. Shirley M. Faricimab: first approval. Drugs 2022; 82 (7): 825-830. https://doi.org/10.1007/s40265-022-01713-3.

41. Hattenbach L.O., Abreu F., Arrisi P., et al. BALATON and COMINO: Phase III randomized clinical trials of faricimab for retinal vein occlusion: study design and rationale. Ophthalmol Sci 2023; 3 (3): 100302. https://doi.org/10.1016/j.xops.2023.100302.

42. Al-Zamil M., Kulikova N.G., Vasil`eva E.S., Zhuk Y.M. The effectiveness of electrophoresis with caripain in the treatment of discogenic radiculopathy in the cervical spine. Clinical case. Russian Journal of Physiotherapy, Balneology and Rehabilitation 2020; 19 (1): 65-68. (In Russian). https://doi.org/10.17816/1681-3456-2020-19-1-10

43. Dagash H., McCaffrey S., Mellor K., et al. Tap water iontophoresis in the treatment of pediatric hyperhidrosis. J Pediatr Surg, 2017; 52 (2,): 309-312. https://doi.org/10.1016/j.jpedsurg.2016.11.026.

44. Wang Y., Thakur R., Fan Q., Michniak B. Transdermal iontophoresis: combination strategies to improve transdermal ion-tophoretic drug delivery. Eur J Pharm Biopharm 2005; 60: 179–191.

45. Sheikh N.K., Dua A. Iontophoresis analgesic medications, 2023, 31. In: StatPearls [Internet]. Treasure Is-land (FL): StatPearls Publishing; 2025 Jan–. PMID: 31971730.

46. Cázares-Delgadillo J., Planard-Luong L., Gregoire S., et al. Investigation of different iontophoretic currents profiles for short-term applications in cosmetics. Pharmaceutics. 2018, 10, 266.

47. Bakshi P., Vora D., Hemmady K., Banga A.K. Iontophoretic skin delivery systems: success and failures. Int J Pharm 2020; 586: 119584.

48. Liatsopoulou A., Varvaresou A., Mellou F., Protopapa E. Iontophoresis in dermal delivery: A review of applications in dermato-cosmetic and aesthetic sciences. Int J Cosmet Sci 2023; 45 (2): 117-132. https://doi.org/10.1111/ics.12824.

49. Kim K.T., Lee J., Kim M.H., et al. Novel reverse electrodialysis-driven ion-tophoretic system for topical and transdermal delivery of poorly permeable therapeutic agents. Drug Deliv 2017; 24: 1204–1215.

50. Swift M.J., Crago P.E., Grill W.M. Applied electric fields accelerate the diffussion rat and increase the dif-fusion distance of DiI in fixed tissue. J Neurosci Methods 2005; 141: 155–163. https://doi.org/10.1016/j.jneumeth.2004.06.011.

51. Madison R.D., Robinson G.A., Krarup C., et al. In vitro electrophoresis and in vivo electrophysiology of peripheral nerve using DC field stimulation. J Neurosci Methods 2014; 30 (225): 90-96. https://doi.org/10.1016/j.jneumeth.2014.01.018.

52. Kiernan M.C., Bostock H. Effects of membrane polarization and ischaemia on the excitability properties of human motor axons. Brain 2000; 123 (Pt 12): 2542-2551. https://doi.org/10.1093/brain/123.12.2542.

53. Poo M., Lam J.W., Orida N., Chao A.W. Electrophoresis and diffusion in the plane of the cell membrane. Biophys J. 1979; 26 (1): 1-21. https://doi.org/10.1016/S0006-3495(79)85231-5.

54. Stollberg J., Fraser S.E. Acetylcholine receptors and concanavalin A-binding sites on cultured Xenopus muscle cells: elec-trophoresis, diffusion, and aggregation. J Cell Biol 1988; 107 (4): 1397-1408. https://doi.org/10.1083/jcb.107.4.1397.

55. Zhao M., Dick A., Forrester J.V., McCaig C.D. Electric field-directed cell motility involves up-regulated expression and asymmetric redistribution of the epidermal growth factor receptors and is enhanced by fibronectin and laminin. Mol Biol Cell 1999; 10 (4): 1259-1276. https://doi.org/10.1091/mbc.10.4.1259.

56. Astakhov Yu.S., Kiryanova V.V., Maksimov A.V., et al. Optimization of treatment of the dry form of age-related macular degeneration by endonasal electrophoresis with the drug "Retinalamin". Ophthalmological Reports 2010; 3 (1): 69-77.

57. Antonov A,A. Experimental studies of Retinalamin efficacy. National Journal of Glaucoma 2024; 23 (2): 45-52. (In Russian)

58. Kabardina E.V., Smekalkina L.V., Shurygina I.P., Khripunova O.V. Prospects for the use of pharmaco-physiotherapeutic methods in the complex treatment of macular retinal edema in patients with postthrombotic retinopathy. Journal of New Medical Technologies 2023; 3: 101-107. (In Russian). https://doi.org/10.24412/2075-4094-2023-3-3-5

59. Saidov T., Yangieva N. Khamidullaev F., et al. Clinical and functional effectiveness of endonasal electro-phoresis in com-bination with electrostimulation in complex therapy of glaucomatous optic neuropathy. The American Journal of Medical Sciences and Pharmaceutical Research 2021; 3 (3): 138-144. https://inlibrary.uz/index.php/archive/article/view/13877.

60. Antonov A.A., Makarova A.S., Reshchikova V.S. Experimental studies of Retinalamin efficacy. National Journal of Glaucoma. 2017,16, 3, 98-102. (In Russian)

61. Antonov A.A. Experimental studies of Retinalamin efficacy. National Journal of Glaucoma 2024; 23 (2): 45-52. (In Russian)

62. Khalili M.R., Shadmani A., Sanie-Jahromi F. Application of electrostimulation and magnetic stimulation in patients with optic neuropathy: A mechanistic review. Dev Neurobiol 2024; 84 (3): 236-248. https://doi.org/10.1002/dneu.22949.

63. Wu H., Li C., Masood M., et al. Static magnetic fields regulate T-type calcium ion channels and mediate mesenchymal stem cells proliferation. Cells 2022; 11 (15): 2460. https://doi.org/10.3390/cells11152460.

64. Yan J., Dong L., Zhang B., Qi N. Effects of extremely low-frequency magnetic field on growth and differ-entiation of human mesenchymal stem cells. Electromagn Biol Med 2010; 29 (4): 165-176. https://doi.org/10.3109/01676830.2010.505490.

65. Smekalkina L.V., Shurygina I.P., Kabardina EV. Long-term results of complex pharmacotherapy and physiotherapy in anti-angiogenic therapy for macular edema in patients with post-thrombotic retinopathy. Modern Problems of Science and Education 2023; 3. https://doi.org/10.17513/spno.32597 (In Russian)

66. Kabardina E.V., Smekalkina L.V., Shurygina I.P. Comprehensive rehabilitation of patients after thrombosis of the superior temporal branch of the central retinal vein using physiotherapeutic treatment methods. In: Abstract Book of the VIII All-Russian Congress "Physiotherapy. Exercise Therapy. Rehabilitation. Sports Medicine" 2025: 15-16. (In Russian)

67. Kabardina E.V., Smekalkina L.V., Naprienko M.V., et al. Clinical and rehabilitative aspects of retinal vein occlusions: A textbook. Moscow: Sechenov University Publishing House; 2025. 60 p. (In Russian)

68. Davydov D.V., Yakovlev A.E., Vybornaya T.R. Clinical functional results of the continuous electromag-netic stimulation in patients with optic nerve partial atrophy. Ophthalmology Reports 2017; 10 (2,): 29-35. https://doi.org/10.17816/OV10229-35.

69. Murthy S.N., Sammeta S.M., Bowers C. Magnetophoresis for enhancing transdermal drug delivery: Mechanistic studies and patch design. J Control Release 2010; 148 (2): 197-203. https://doi.org/10.1016/j.jconrel.2010.08.015.

70. Ahn S.J. Retinal thickness analysis using optical coherence tomography: diagnostic and monitoring applications in retinal diseases. Diagnostics (Basel) 2025; 15 (7): 833. https://doi.org/10.3390/diagnostics15070833.

71. Dhoot D.S., Shah C.P., Silva F.Q., et al. Impact of central sub-field thickness fluctuations on visual outcomes in neovascular age-related macular degeneration in the VIEW trials. J Vitreoretin Dis 2025; 20: 24741264251359902. https://doi.org/10.1177/24741264251359902.

72. Rattanalert K., Bhurayanontachai P., Ratanasukon M., et al. Correlation of retinal thickness, macular volume, and their fluctuation with visual outcomes in patients with macular edema due to retinal vein occlusion. Int J Retina Vitreous 2025; 11 (1): 67. https://doi.org/10.1186/s40942-025-00693-2.

73. Chan A., Duker J.S., Ko T.H., et al. Normal macular thickness measurements in healthy eyes using Stratus optical coherence tomography. Arch Ophthalmol 2006; 124 (2): 193-198. https://doi.org/10.1001/archopht.124.2.193.

74. Oderinlo O., Bogunjoko T., Hassan A.O., et al. Normal central foveal thickness in a thousand eyes of healthy patients in Sub Saharan Africa using fourier domain optical coherence tomography. Nigerian Journal of Clinical Practice 2023; 26 (3): 331-335. https://doi.org/10.4103/njcp.njcp_318_22

75. Mititelu M., Uschner D., Doherty L., et al. Retinal thickness and morphology changes on OCT in youth with type 2 diabetes: findings from the TODAY study. Ophthalmol Sci 2022; 2 (4): 100191. https://doi.org/10.1016/j.xops.2022.100191.

76. Liu T., Hu A.Y., Kaines A., et al. A pilot study of normative data for macular thickness and volume measurements using cirrus high-definition optical coherence tomography. Retina 2011; 31 (9): 1944-1950. https://doi.org/10.1097/IAE.0b013e31820d3f13.

77. Arruabarrena C., Rodríguez-Miguel A., de Aragón-Gómez, F., et al. Normative data for macular thickness and volume for optical coherence tomography in a diabetic population without maculopathies. J Clin Med 2023; 12 (16): 5232. https://doi.org/10.3390/jcm12165232.

78. Pokharel A., Shrestha G.S., Shrestha J.B. Macular thickness and macular volume measurements using spectral domain optical coherence tomography in normal Nepalese eyes. Clin Ophthalmol 2016; 21 (10): 511-519. https://doi.org/10.2147/OPTH.S95956.

79. Al-Zamil W.M., Al-Zwaidi F.M., Yassin S.A. Macular thickness in healthy Saudi adults. A spectral-domain optical coherence tomography study. Saudi Med J 2017; 38 (1): 63-69. https://doi.org/10.15537/smj.2017.1.17565.

80. Mikhailova O.B., Farennikova E.S. Specifics of psychological well-being of different occupational groups' representatives during the COVID-19 pandemic. World of Science. Pedagogy and Psychology 2020; 4 (8): 67PSMN420 Available at: https://mir-nauki.com/PDF/67PSMN420.pdf (In Russian)

81. Zhmerenetsky K.V., Rzyankina M.F., Potapova K.E. Psychosocial aspects of self-assessment of the health of children and adolescents in changed epidemiological conditions. Mental Health 2022; 17 (7): 24-28. https://doi.org/10.25557/2074-014X.2022.07.24-28

82. Campa C., Alivernini G., Bolletta E., et al. Anti-VEGF therapy for retinal vein occlusions. Curr Drug Targets 2016; 17 (3): 328-336. https://doi.org/10.2174/1573399811666150615151324.

83. Dinah C., Dodds M., Lotery A., et al. Treatment patterns and long-term outcomes in anti-VEGF-treated macular oedema secondary to retinal vein occlusion: a retrospective observational study. Eye (Lond) 2025; 14. https://doi.org/10.1038/s41433-025-04089-2.

84. Corazza P.D., Alterio F.M., Savastano M.C., et al. Long-term outcomes of anti-VEGF treatment of macular oedema due to retinal vein occlusions. Eur J Ophthalmol 2022; 32 (6): 3536-3546. https://doi.org/10.1177/11206721221085870.

85. Subhi Y., Potapenko I., Hajari J.N., la Cour M. Prognostic modelling of number of patients with retinal vein occlusion in anti-VEGF therapy. Acta Ophthalmol 2024; 102 (3): 318-325. https://doi.org/10.1111/aos.15721.

86. Chen K.Y., Chan H.C., Chan C.M. Effectiveness and safety of anti-vascular endothelial growth factor therapies for macular edema in retinal vein occlusion: A systematic review and network meta-analysis of randomized controlled trials. Surv Ophthalmol 2025; 70 (6): 1067-1089. https://doi.org/10.1016/j.survophthal.2025.05.008.

87. Özmert E., Arslan U. Management of deep retinal capillary ischemia by electromagnetic stimulation and platelet-rich plasma: preliminary clinical results. Adv Ther 2019; 36 (9): 2273-2286. https://doi.org/10.1007/s12325-019-01040-2.

88. Makarov I.A., Voronkov Yu.I. The role of low-frequency TRANS-orbital magnetic stimulation in normalization of intraocular pressure in patients with primary open-angle glaucoma. Ophthalmology in Russia 2016; 13 (4): 273-277. (In Russian). https://doi.org/10.18008/1816-5095-2016-4-273-277

89. Joseph J.T., Jammigumpula A., Jaise J., et al. Safety of repetitive transcranial magnetic stimulation in retinal detachment: A case report and brief review. J ECT 2024; 40 (3): e11-e12. https://doi.org/10.1097/YCT.0000000000001000.

90. Khalili M.R., Shadmani A., Sanie-Jahromi F. Application of electrostimulation and magnetic stimulation in patients with optic neuropathy: A mechanistic review. Dev Neurobiol 2024; 84 (3): 236-248. https://doi.org/10.1002/dneu.22949.

91. Davydov D.V., Yakovlev A.E., Vybornaya T.R. Clinical functional results of the continuous electromag-netic stimulation in patients with optic nerve partial atrophy. Ophthalmology Reports 2017; 10 (2): 29-35. https://doi.org/10.17816/OV10229-35.

92. Ibraheem M., El-Fakharany E., Husseiny S., Mohammed F. An overview on Hyaluronidase enzyme types, mode of action, assay and therapeutic applications. Journal of Scientific Research in Science. 2024; 41: 1-17. https://doi.org/10.21608/jsrs.2024.273369.1125.

93. Razumovskaya A.M., Razumovsky M.I., Koroviansky Yu.A., Razumovsky E.S. Еstimation of therapeutic effect of endonasal electrophorosis with methylethylpyridinol in partial optic nerve atrophy. Ophthalmology in Russia 2018; 15 (2): 219-224. (In Russian). https://doi.org/10.18008/1816-5095-2018-2-219-224.